AIM ImmunoTech to Participate in the Virtual Investor Summer Spotlight Series
05 Julho 2023 - 9:35AM
AIM ImmunoTech Inc. (NYSE American:
AIM) (“AIM” or the “Company”), an immuno-pharma
company focused on the research and development of therapeutics to
treat multiple types of cancers, immune disorders, and viral
diseases, including COVID-19, the disease caused by the SARS-CoV-2
virus, today announced that Thomas K. Equels, MS JD, Chief
Executive Officer of AIM ImmunoTech and Dr. Christopher McAleer,
Scientific Officer at AIM ImmunoTech will participate in the
Virtual Investor Summer Spotlight Series on Wednesday, July 12,
2023 at 11:00 AM ET.
A live video webcast of the presentation will be
available on the Events page of the Company’s website
(aimimmuno.com). A webcast replay will be available two hours
following the live presentation and will be accessible for 90
days.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company
focused on the research and development of therapeutics to treat
multiple types of cancers, immune disorders and viral diseases,
including COVID-19. The Company’s lead product is a first-in-class
investigational drug called Ampligen® (rintatolimod), a dsRNA and
highly selective TLR3 agonist immuno-modulator with broad spectrum
activity in clinical trials for globally important cancers, viral
diseases and disorders of the immune system.
For more information, please
visit aimimmuno.com and connect with the Company
on Twitter, LinkedIn, and Facebook.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
AIM@jtcir.com
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
AIM ImmunoTech (AMEX:AIM)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024